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ABSTRACT
To comprehend whether corporate social responsibility (CSR) in pharma is more of a corporate hypocrisy where firms and organizations tend to 
marginalize their employees and the environment at large. The present study is case based, and an attempt has been made to analyze probable driving 
reasons behind the corporate behavior exhibited by pharma industries. CSR is understood differently by different beneficiaries but usually refers to 
serving the citizens, population of communities, and the larger society in a way that goes beyond what is legally required of a firm. Though numerous 
programs and schemes have been launched for their upliftment, it is all an eye wash which is intended for the internal benefit of the organization. 
Corporate these days, as per the Companies Act should report spend of 2% of their profits as pronounced in the CSR and pharmaceutical companies 
are no exemption to it. As per Section 135 of the Companies Act 2013, it is recommended that companies having revenue above Rs. 1,000 crore and 
profit more than Rs. 5 crore should report what they spend for CSR. Companies these days often utilize CSR as a brand building exercise, engagement 
of employees, helping the local community around their firm, or even as a fame generating spot for the themes of the chairman’s spouse. Thus, it is 
obvious that the social responsibility of pharmaceutical business sector is mainly to increase their profit, increase their shareholder activism, and 
investment in the community.
Keywords: Corporate social responsibility, Hypocrisy, Pharmaceutical industries, Society and organization.
INTRODUCTION
Corporate social responsibility (CSR) is an emerging expression that 
has no benchmark definition or a completely acknowledged meaning 
with standard criteria. This CSR in the business arena plays a key role 
on occupation and wealth formation in society; CSR is very frequently 
understood to be the way a firm strikes a balance or amalgamation of 
economic, environmental, and social imperatives while at the same 
time addresses the shareholder and stakeholder outlook. CSR is 
normally accepted as applying to firms wherever they function in the 
domestic and global economy. The way businesses engage/involve the 
shareholders, employees, customers, suppliers, governments, non-
governmental organizations, international organizations, and other 
stakeholders are usually a key feature of the concept. While business 
compliance with laws and regulations on social, environmental, and 
economic objectives set the official level of CSR performance, CSR 
is often regarded as concerning the private sector commitments and 
performance that expand beyond the base of conformity with laws.
CSR is understood differently by different beneficiaries but usually 
refers to serving the citizens, population of communities, and the 
larger society in a way that goes beyond what is legally required of a 
firm. From a progressive business standpoint, CSR usually involves 
focusing on new opportunities as a way to respond to interrelated 
economic, societal, and environmental demands in the marketplace. 
Most of the firms consider that this focus provides a crystal clear 
competitive benefit and stirs corporate innovation. CSR is by and large 
seen as the business donation to building a sustainable society which 
has been distinct as “development that meet the needs of the present 
without compromising the ability of future generations to meet their 
own needs,” and is focused to achieve the amalgamation of economic, 
environmental, and social imperatives. The concept of CSR is seen 
to overlap and is synonymous with many terms such as corporate 
stewardship, corporate citizenship, corporate responsibility, corporate 
accountability, and corporate sustainability.
CSR-related activities in pharmaceutical companies concern around 
health and disaster, environmental sustainability and preservation, 
health, critical and palliative care, education and awareness building, 
drug trials and insurance coverage, human rights, human resource 
management practices, corporate governance, community development, 
protection of consumers, labor protection, supplier relations, business 
ethics, and stakeholder rights. Corporations are motivated to involve 
stakeholders in their decision-making and to address societal issues 
since today’s stakeholders are increasingly responsive to the impact 
of corporate decisions on society and their environment at large. The 
stakeholders can reward or punish corporations. Corporations can 
be motivated to change their corporate behavior in response to the 
business case which a CSR approach potentially promises. This includes:
1.	 Increased	monetary	performance	and	profitability	 (e.g.,	 through	
eco-efficiency),
2. Enhanced accountability and assessments from the investing 
community,
3. Improved commitment and loyalty from the employees,
4. Reduction in liability as a result of stronger relations with 
communities, and
5. Improved repute and branding.
In the recent years, CSR is more of a corporate hypocrisy where 
firms and organizations tend to marginalize their employees and the 
environment at large. Though numerous programs and schemes have 
been launched for their upliftment, it is all an eye wash which is intended 
for the internal benefit of the organization. Corporate these days, with 
reference to the Companies Act says ought to spend 2% of their profits 
as deploy in CSR. According to Section 135 of the Companies Act 2013, 
all companies with revenues above Rs. 1,000 crore and profit more 
Rs. 5 crore should spend on CSR. Companies most of the times use 
CSR as brand building exercise, engagement of employees, helping the 
local community around their concern, or even as a parking spot for 
the pet themes of the chairman’s spouse. Thus, it is obvious that the 
social responsibility of business sector is mainly to increase their profit, 
increase their shareholder activism, and investment in the community. 
In this study, an attempt has been made to analyze probable driving 
reasons behind the corporate behavior exhibited by an organization.
CSR AND PHARMACEUTICAL COMPANIES IN INDIA
The companies’ bill which was passed in the Lok Sabha on December 
18, 2012, has clearly indicated that the pharma industries in India will 
have to spend between Rs. 300 and 325 crore in the years to come as 
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a part of their CSR. Though few of the pharmaceutical companies have 
initiated activities and programs corresponding to the CSR not many 
have taken it seriously. In an article by the Pharmabiz review, nearly 
79 pharmaceutical companies are yet to spend two per cent of their 
average net profits on social activities which account to Rs. 325 crore. 
It has been also estimated that 30 Indian companies clocked net sales 
of over Rs. 1,000 crore during 2011-12, and these companies achieved 
aggregate net sales of Rs. 96,957 crore. With Ranbaxy topping with net 
sales of Rs. 9, 958 crore, additionally, 32 companies recorded net worth 
(equity capital plus reserves and surplus) of Rs. 500 crore or more in 
2011-12 and 79 companies jagged up an average net profit of over 
Rs. 5 crore during last 3 years. Several Indian pharma companies are 
contributing to improve lives and create a healthier world under CSR 
objectives. Further, major companies instituted a Whistle Blower Policy, 
which empowers employees to raise their concerns or highlights issues 
if there are any discriminatory or gender-biased conducts, fraudulent 
business practices, unethical behavior, or violation of Code of Conduct. 
Indian majors, such as Dr. Reddy’s Laboratories (DRL), Biocon, Lupin, 
Cadila Healthcare, and Jubilant Life sciences, are already engaged in CSR 
activities. Even multinational companies, such as Ranbaxy Laboratories, 
Glaxo Smith Kline Pharma, and Pfizer, are making investments under 
CSR [1].
Ranbaxy has created a core group of 93 persons including 33 medical 
officers, 37 auxiliary nurse midwives, and other paramedics and 19 
support staff enable to operate 18 mobile healthcare vans and on urban 
family welfare center, providing services to over to 6.50 lakhs people in 
the northern and central parts of India. The company initiated Ranbaxy 
Sanjeevan Swasthya Sewa, a public private partnership between the 
Punjab State governments during 2010. The focus is mainly on primary 
healthcare and prevention and early detection of commonly found 
cancers of the cervix, breast, and oral cavity. The program covers a total 
population of about 4.50 lakh in around 180 villages in Punjab.
DRL has set up Dr. Reddy’s Foundation (DRF) during 1996 as a non-
profit arm. DRF plays the role of a change agent in the social sector, 
by recognizing and pursuing new opportunities to serve that mission 
and by engaging in a process of continuous innovation adaptation 
and learning. Cadila Healthcare has promoted CSR program under 
Zydus Srishti. Its CSR activities are focused on the three core areas of 
Swasthya (Health, Safety, and Environment). Shiksha (Education and 
Shodh [Research]). Over the last 17 years, these CSR initiatives have 
helped the company to translate its mission to create healthy and 
happy communities in reality. Biocon, thorough Biocon Foundation, 
has implemented CSR in several districts of Karnataka with its focus on 
critical health areas which is often neglected reduced awareness levels. 
It has initiated a research study in Kaladgi, Bagalkot to study whether 
an integrated approach to anemia management will help women to 
maintain higher levels of hemoglobin, consistently. The company is has 
also planned to start Tobacco Cessation Centers in all its clinics. The 
nine Arogya Raksha Clinics continue to provide clinical services to the 
communities that surround it treating over 63,000 patients in 2011-12.
Lupin, through its Lupin Human Welfare and Research Foundation is 
supporting the cause of rural development initiatives to over 25 lakhs 
people across 3,000 villages in the State of Rajasthan, Madhya Pradesh, 
Maharashtra, and Uttarakhand in India with its mission of uplifting the 
lives of “1 Crore” people residing in rural India above the poverty line.
Glaxo Smith Kline Pharma as its CSR continues its services toward social 
development and implementing rural development initiatives through 
Gramin Arogya Vikas Sanstha in Nashik and has extended support to 
Institute for Indian mother and child, a non-government organization 
reaching out to 1.30 lakhs patients in Kolkata. It also supports four 
voluntary organizations for cancer care [1].
THE NEGATIVE SIDE OF CSR IN PHARMACEUTICAL COMPANIES
Milton Friedman along with his associates has argued that a corporation’s 
principle is to maximize returns to its shareholders and that obeying 
the laws of the jurisdictions within which it operates constitutes 
socially responsible behavior [2]. While some CSR supporters claim 
that companies practicing CSR, especially in developing countries, are 
less likely to exploit workers and communities, critics claim that CSR 
itself imposes outside values on local communities with unpredictable 
outcomes [3]. Better governmental regulation and enforcement, rather 
than voluntary measures, are an alternative to CSR that moves decision-
making and resource allocation from public to private bodies. However, 
critics claim that effective CSR must be voluntary as mandatory social 
responsibility programs regulated by the government interferes 
with people’s own plans and preferences, distorts the allocation of 
resources, and increases the likelihood of irresponsible decisions [4]. 
Some critics consider CSR programs carried out by companies are 
mainly to distract the general population from ethical questions 
posed on their core operations. They squabble that the reputational 
benefits that CSR companies receive and demonstrate the hypocrisy 
of the approach [5]. According to Porter and Kramer (2002), most of 
the business and corporate are involved in philanthropic activities and 
programs in all most all sectors under the banner of CSR [6]. It is seen 
that CSR is gaining momentum of harnessing the business arena and 
the global community with its objectives and interests dovetailed for 
the benefit of the large as seen the United Nations Global Compact on 
Corporate Sustainability [7]. It has been found by Leisinger (2005) that 
pharmaceutical companies and their businesses are directly linked 
to the welfare of the population and their decision on business has a 
tremendous impact on the well-being of the human and, therefore, CSR 
becomes necessary. These firms have been critically viewed for fixing 
high prices for their products on life-saving drugs and slowness in 
response to the demands of the poor populations [8]. In relation to it, 
in the recent past two decades, companies engaged in pharmaceutical 
products have considerably enlarged CSR efforts, particularly for 
the low and middle-income countries that have their majority being 
affected by diseases in the global scenario [9,10]. The HIV/AIDS 
pandemic has recently exaggerated the pressures to actively work to 
promote societal well-being [11]. In a study by Hwang (2012), it has 
been highlighted that pharmaceutical companies have been criticized 
for using CSR to mend compromised reputations or to undo public 
viewpoint on their commercial happenings being unethical [12]. Many 
papers have explored as to whether pharmaceutical companies have 
taken into consideration their obligation toward human rights [13-16], 
in spite of all studies, there is a limited literature which focuses on CSR 
comprehensively, instead focusing on the pricing of drugs and licensing 
and product patency. There is limited literature on global health and 
CSR [17,18].
FACTS ON NEGATIVE IMPACT OF CSR IN PHARMACEUTICAL 
COMPANIES
Business Standard of Delhi front-paged a story that pharmaceutical 
multinationals Novartis, Pfizer, Bayer, Bristol-Myers Squibb were 
involved in clinical trials in India that killed 438 people in 2011. Quoting 
data from the Drugs Controller General of India (DCGI), the newspaper 
listed the companies and the fatalities that resulted in the trials of each 
of these companies which also included a handful of domestic drugs 
manufacturers [19]. Most pharmaceutical companies conduct trials 
through Contract Research Organizations, which have mushroomed 
to take advantage of this booming business opportunity. Its market in 
India has grown from Rs. 423 crore in 2005 to Rs. 1,611 crore in 2010. It 
is expected to cross Rs. 2,721 crore by 2012, says Centre for Research on 
Multinational Corporations (SOMO). Investigators in private hospitals 
are paid much more. Money ranges from Rs. 70,000 to Rs. 1 lakh per 
patient. Regulatory authorities have no control over contract research 
organizations (CROs). They are not mentioned in Drugs and Cosmetics 
Act and are not required to get registered. These organizations have 
mushroomed on their own to make money [20]. A government panel, 
which probed seven deaths due to human papillomavirus vaccine in 
Andhra Pradesh and Gujarat, stated in its report there was no mention 
of insurance cover in the pharmaceutical company’s trial protocol. 
“Instead of giving insurance cover to girls, non-profit PATH which 
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conducted the trials got insurance cover for itself,” says Brinda Karat, 
Rajya Sabha member. These grave issues clearly indicate that there 
still exist inadequacies in the approval process and responsibilities 
of the approval bodies including the Ethics Committees [21]. It is 
also reported that no progress has been made to enforce stringent 
regulations regarding clinical trials in India. The bill drafted in 2002 
based on the guidelines of the Indian Council of Medical Research and 
submitted in 2007 to the Ministry of Health and Family Welfare has not 
taken this issue into consideration as the government is pressurized 
by the pharmaceutical industries. The article has also highlighted 
that unlike in the Western countries; the guilty is never punished in 
India [22]. CSIR sanctioned a project on “Process for Tamiflu-a drug to 
combat the menace of avian flu” implemented by the National Chemical 
Laboratory, Pune with a budget allocation of Rs. 25 lakh for a duration 
of 6 months. The project geared up as a result of threat of bird flu 
pandemic in the country. CSIR aimed to develop the process for the 
indigenous production of Tamiflu drug used in the treatment of bird flu, 
so as to become self-reliant in drug production and stockpile sufficient 
quantity. As there was already a patented process for the production of 
Tamiflu, CSIR took up the project to develop a non-infringing process 
for development of the drug as reported by the Comptroller and Auditor 
General of India (CAG). The Indian Institute of Chemical Technology, 
Hyderabad was included as a partner with an additional allocation of 
Rs. 25 lakh. However, NCL and IICT failed to develop a non-infringing 
process for development of Tamiflu. The project was shelved after 
incurring an expenditure of Rs. 39, 5353 lakhs. The audit observed 
that the project was sanctioned in violation of project formulation 
guidelines. It was also revealed that Indian companies permitted by 
the government to produce generic versions of the drug had got the 
process from abroad as a package from the original manufacturer, and 
the developed process could not be utilized. CAG said that the purpose 
to become self-sufficient in the event of a threat of the disease in future 
was also defeated [23].
More than 80% of the people living with HIV in the state are yet to get 
treatment. Of the estimated 1.25 lakh people living with HIV (PLHIV) 
in Uttar Pradesh, only 25,278 are getting free anti-retroviral therapy 
(ART) treatment, according to data from the UP State AIDS Control 
Society. Here, arises the need of CSR and pharmaceutical companies 
to combat the scary situation to do everything possible to test and 
treat the untapped patients. Pharmaceutical Companies such as Cipla 
specialized in drug manufacturing should as part of CSR concentrate 
mainly on combating the menace of HIV/AIDS at the national wide than 
plunging into other schemes and programs [24]. It has been estimated 
that on an average, 68 people die every day due to cancer in the state of 
Gujarat. A total of 24,667 people had died of cancer in 2014 and in 2013, 
it was 23,966. According to the figures, Gujarat was ranked 10th in term 
of prevalence and deaths in the country. Uttar Pradesh topped the chart 
with 82,121 deaths, followed by Maharashtra with 44,924. Though 
pharma companies are engaged in varied activities and schemes in the 
limelight of CSR it is necessary that efforts are taken to tackle issues 
targeted on specific health hazards of a particular region than simply 
doing away with a program just for records and fame [25].
India relies on Medical Council of India (MCI) to prevent malpractices. 
The MCI notification on December 10, 2009, prohibits all healthcare 
professionals in India from accepting benefits from pharmaceutical 
or allied healthcare companies for any purpose, including educational 
programs or sponsorships even if the event is organized by independent 
third party organizations. Seeking a relaxation from the notification, the 
Department of Pharmaceutical, Ministry of Chemical and Fertilizers, 
sent a letter to the Ministry of Family and Welfare a year ago, saying 
continued medical education is essential for professional growth and 
will eventually benefit patients. The ministry has not responded yet.
K V Babu, a doctor who accessed the pharmaceutical department’s 
letter through a Right to Information application, points out that the 
letter was sent at the behest of the pharma industry and doctors did not 
have any problem with the MCI notification. Arun Gupta, the convener of 
Delhi-based non-profit Alliance against Conflict of Interest, says despite 
MCI’s decision, companies are still engaged in malpractices. He says 
Johnson and Johnson in its annual report for 2012 revealed having paid 
more than Rs. 1 crore in 2011-12 to Indian Academy of Pediatrics [26].
Statements by Chairperson-cum-managing director of Mankind 
Pharma Ltd R C Juneja says if companies stop paying doctors, drugs will 
be sold only on the basis of their efficacy and expenses of companies 
will reduce. Sharma, vice-president of Pharmacy Council of India, has a 
similar view. He says companies can cut cost by restricting unwarranted 
expenditure, and this would benefit patients. These versions purport 
that alleged malpractices of pharma companies have been ignored. 
It could also be interpreted that when doctors are given freebies and 
gifts they might also recommend medicines which are of undermined 
quality and combination of drugs which again would be a threat to the 
human population [27].
Drug resistance is being reported in every sort of infectious disease. 
A recent survey found that 60% of infectious disease specialists had 
encountered infections that were resistant to every antibiotic. The 
World Health Organization categorizes antimicrobial resistance as 
one of the three greatest threats to human health. If developing these 
antibiotics is stopped, we would face tremendous public health costs. 
Antibiotics deliver a much lower return on investment than other types 
of medicines. The paper on “call to arms” from the Infectious Diseases 
Society of America in 2008 concluded that antibiotics are less desirable 
to drug companies and venture capitalists because they are more 
successful than other drugs and moreover it is long-term therapy - not 
cures - that drives interest in drug development. The products that make 
the most money for their shareholders, such as Viagra or Lipitor, while 
through tax bungs, grants or public-private partnerships pay them to 
research and develop what makes millions instead of billions. The public 
bares the risk, but the companies take the profit. If these companies 
were brought into the public sector under the rubric of the National 
Institutes of Health or a similar stand-alone body, the money made from 
the profitable drugs could subsidize the research and development of 
less profitable drugs in turn for allowing more money to be spent on 
drug research and development. Placed in the public sector, barriers to 
open pharmaceutical research would dissolve, which would accelerate 
outcomes and limit duplication. The company’s profit-seeking hurts the 
poor of the developed and developing the world, which cannot afford 
the drugs, and hence drug firms have pushed millions into the arms 
of alternative medicine quackery [28]. The most Indian formulation 
makers prefer to import bulk drugs from China because it is cheaper to 
do so, and in fact, in the last few years, have become heavily dependent 
on Chinese imports. A report in July this year by the Associated 
Chambers of Commerce and Industry of India has highlighted that lack 
of self-sufficiency poses a significant risk. It has also pointed out that 
any deterioration in the relationship with China can potentially result in 
severe shortages in the supply of essential drugs to the country and, in 
addition, China could easily increase prices of some of the drugs where 
it enjoys a virtual monopoly. Therefore, why not pharma companies 
widen their perspective of CSR to tackle these kinds of issues and try to 
manufacture the imported drugs to serve the poor [29].
Health these days is viewed more a commodity to be purchased 
Ayurveda, often called the science of healing and rejuvenation is 
shrinking not because people do not want it but because it is not 
properly placed in the public mind. The challenge of the physicians and 
that of the pharma industries today is to change the form of Ayurveda 
without distorting its principles which the Indian pharmaceutical 
companies have neglected. With the advent of the Western ethos-
centric worldview the question of which model of leadership health 
issues we adopt has come about. It is the right time the pharmaceutical 
companies promote the culture and tradition based health model and 
practices. India should have an Ayurveda based integrative model [30].
RECOMMENDATIONS
Transparency and accountability need to be improved with a common 
understanding of what CSR means to health-related and pharmaceutical 
companies. A common metrics of evaluation could be done to on 
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a uniform basis. It must be made mandatory for pharmaceutical 
companies to outline the quantitative and qualitative indicators with 
which their CSR effectives could be measured. Indices though exist 
with few companies still needs to be developed and strengthened. Very 
many pharmaceutical industries in India do not have formal written 
CSR policies or a certified system of management for their CSR. The 
resources allotted by the majority of the companies do not correspond 
to their profit and take shape in the light of deficient funds with mere 
advertising of programs. Hence, systematic approaches need to be 
followed when it comes to deploying of investments for CSR practices 
of a company. Medical advancements must be made truly philanthropic; 
the profit motive has to be removed. If the objective is to cure rare 
diseases, there needs to be increased the budget allocation for the 
National Institutes of Health and other research initiatives instead of 
gala balls, marathon runs and donor drives, higher taxes on the same 
rich benefactors could be used to fund the research. Biotech patents 
developed through venture philanthropy should not have exclusive 
rights attached to them.
The development of generic versions of drugs into the market goes 
a long way toward keeping health care costs down and not driving 
the uninsured into debt. The committee set up by the government 
headed by the Secretary, Department of Health Research; to look into 
the issues of bulk drugs/active pharmaceutical ingredients [31]. The 
government should prioritize the diseases on which trials are to be 
conducted. Health experts suggest transparency to improve the system. 
Independent audits of clinical trials should be conducted and made 
public. There must be an independent authority to audit DCGI and 
ethics committees which regulate and monitor clinical trials in India. 
According to Satish Reddy, President, Indian Pharmaceutical Alliance 
and Chairman of drug maker DRL to stem out Chinese bulk drugs flow 
into India the government in collaboration with the pharmaceutical 
industries creates industry clusters with state support to enjoy basic 
facilities such as power at competitive prices which in turn will make 
industry to look to investing in capacities that achieve scale and reduce 
costs [32].
Pharmaceutical companies need to take efforts toward promoting 
an indigenous system of medicines which were used in different 
combinations with minimal side effects on the human population.
CONCLUSION
The concept of CSR has gained importance from all avenues. 
Pharmaceutical companies need to realize that mere government alone 
will not be able to tackle the health-related menace of the society and it 
becomes necessary for this industry to have an enlarged understanding 
of CSR. It is high time that drug companies start thinking aloud of their 
CSR activities targeted more into research and development of generic 
drugs to fight diseases, promote indigenous practices and medicines, 
minimize using human samples as guinea pigs and enhance sustained 
efforts to maximize the company’s overall impact on the society and 
stakeholders. It, therefore, becomes imperative that Government in 
collaboration with Pharmaceutical industries keep the welfare of 
citizens as a prime concern than profit earning and multinational 
partnerships.
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